Naomi Dempsey1, Amanda Rosenthal2,3, Nitika Dabas4, Yana Kropotova2, Marc Lippman2,5, Nanette H Bishopric5,6. 1. Divisions of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. naomidempseymd@gmail.com. 2. Divisions of Medical Oncology, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. 3. Department of Medicine, Kaiser Permanente Los Angeles Medical Center, 4867 Sunset Blvd, Los Angeles, CA, 90027, USA. 4. Divisions of Cardiology, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. 5. Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Rd NW, Washington, DC, 20007, USA. 6. MedStar Heart Research Institute, MedStar Washington Hospital Center, 110 Irving St NW, Washington, DC, 20010, USA.
Abstract
PURPOSE: Despite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular contractile function. This review summarizes the risk factors, imaging, and prevention of cardiotoxicity associated with trastuzumab and other HER2-targeted therapies. FINDINGS: Cardiovascular disease risk factors, advanced age, and previous anthracycline treatment predispose to trastuzumab-induced cardiotoxicity (TIC), with anthracycline exposure being the most significant risk factor. Cardiac biomarkers such as troponins and pro-BNP and imaging assessments such as echocardiogram before and during trastuzumab therapy may help in early identification of TIC. Initiation of beta-adrenergic antagonists and angiotensin converting enzyme inhibitors may prevent TIC. Cardiotoxicity rates of other HER2-targeted treatments, such as pertuzumab, T-DM1, lapatinib, neratinib, tucatinib, trastuzumab deruxtecan, and margetuximab, appear to be significantly lower as reported in the pivotal trials which led to their approval. CONCLUSIONS: Risk assessment for TIC should include cardiac imaging assessment and should incorporate prior anthracycline use, the strongest risk factor for TIC. Screening and prediction of cardiotoxicity, referral to a cardio-oncology specialist, and initiation of effective prophylactic therapy may all improve prognosis in patients receiving HER2-directed therapy. Beta blockers and ACE inhibitors appear to mitigate risk of TIC. Anthracycline-free regimens have been proven to be efficacious in early HER2-positive breast cancer and should now be considered the standard of care for early HER2-positive breast cancer. Newer HER2-directed therapies appear to have significantly lower cardiotoxicity compared to trastuzumab, but trials are needed in patients who have experienced TIC and patients with pre-existing cardiac dysfunction.
PURPOSE: Despite great success as a targeted breast cancer therapy, trastuzumab use may be complicated by heart failure and loss of left ventricular contractile function. This review summarizes the risk factors, imaging, and prevention of cardiotoxicity associated with trastuzumab and other HER2-targeted therapies. FINDINGS:Cardiovascular disease risk factors, advanced age, and previous anthracycline treatment predispose to trastuzumab-induced cardiotoxicity (TIC), with anthracycline exposure being the most significant risk factor. Cardiac biomarkers such as troponins and pro-BNP and imaging assessments such as echocardiogram before and during trastuzumab therapy may help in early identification of TIC. Initiation of beta-adrenergic antagonists and angiotensin converting enzymeinhibitors may prevent TIC. Cardiotoxicity rates of other HER2-targeted treatments, such as pertuzumab, T-DM1, lapatinib, neratinib, tucatinib, trastuzumabderuxtecan, and margetuximab, appear to be significantly lower as reported in the pivotal trials which led to their approval. CONCLUSIONS: Risk assessment for TIC should include cardiac imaging assessment and should incorporate prior anthracycline use, the strongest risk factor for TIC. Screening and prediction of cardiotoxicity, referral to a cardio-oncology specialist, and initiation of effective prophylactic therapy may all improve prognosis in patients receiving HER2-directed therapy. Beta blockers and ACEinhibitors appear to mitigate risk of TIC. Anthracycline-free regimens have been proven to be efficacious in early HER2-positive breast cancer and should now be considered the standard of care for early HER2-positive breast cancer. Newer HER2-directed therapies appear to have significantly lower cardiotoxicity compared to trastuzumab, but trials are needed in patients who have experienced TIC and patients with pre-existing cardiac dysfunction.
Authors: Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark Journal: J Clin Oncol Date: 2014-10-20 Impact factor: 44.544
Authors: Jersey Chen; Jessica B Long; Arti Hurria; Cynthia Owusu; Richard M Steingart; Cary P Gross Journal: J Am Coll Cardiol Date: 2012-11-14 Impact factor: 24.094
Authors: Jean C Bikomeye; Janée D Terwoord; Janine H Santos; Andreas M Beyer Journal: Am J Physiol Heart Circ Physiol Date: 2022-08-05 Impact factor: 5.125
Authors: Robert S Ackerman; Aaron R Muncey; Nasrin N Aldawoodi; Rohini Kotha; Rosemarie E Garcia Getting Journal: Curr Oncol Rep Date: 2022-02-10 Impact factor: 5.945
Authors: Romualdo Barroso-Sousa; Paolo Tarantino; Nabihah Tayob; Chau Dang; Denise A Yardley; Steven J Isakoff; Vicente Valero; Meredith Faggen; Therese Mulvey; Ron Bose; Jiani Hu; Douglas Weckstein; Antonio C Wolff; Katherine Reeder-Hayes; Hope S Rugo; Bhuvaneswari Ramaswamy; Dan Zuckerman; Lowell Hart; Vijayakrishna K Gadi; Michael Constantine; Kit Cheng; Frederick Briccetti; Bryan Schneider; Audrey Merrill Garrett; Kelly Marcom; Kathy Albain; Patricia DeFusco; Nadine Tung; Blair Ardman; Rita Nanda; Rachel C Jankowitz; Mothaffar Rimawi; Vandana Abramson; Paula R Pohlmann; Catherine Van Poznak; Andres Forero-Torres; Minetta Liu; Kathryn J Ruddy; Yue Zheng; Shoshana M Rosenberg; Richard D Gelber; Lorenzo Trippa; William Barry; Michelle DeMeo; Harold Burstein; Ann Partridge; Eric P Winer; Ian Krop; Sara M Tolaney Journal: NPJ Breast Cancer Date: 2022-02-16
Authors: Jutta Bergler-Klein; Peter P Rainer; Markus Wallner; Marc-Michael Zaruba; Jakob Dörler; Armin Böhmer; Tamara Buchacher; Maria Frey; Christopher Adlbrecht; Rupert Bartsch; Mariann Gyöngyösi; Ursula-Maria Fürst Journal: Wien Klin Wochenschr Date: 2022-05-04 Impact factor: 2.275